Mature myeloid cells diminish then rapidly recover after Mpc2 deletion. (A) CD45.2 peripheral blood chimerism of mature cell populations was assessed every 2–3 wk in Mpc2 chimeras. Values are normalized to pre-tamoxifen chimerism of each cell type. Data are pooled from three independent experiments. Mean values ± SEM are shown. ****, P < 0.0001 by paired two-way ANOVA with post-hoc Tukey’s multiple comparisons test. (B and C) CD45.2 peripheral blood chimerism of mature cell populations was assessed every 2 wk in Cpt2 (B) or Gls (C) chimeras. Values are normalized to pre-tamoxifen chimerism of each cell type. Mean values ± SEM are shown. Data are pooled from two independent experiments. P values >0.05 by two-way ANOVA with post-hoc Tukey’s multiple comparisons test are not depicted.
Figure 3.

Mature myeloid cells diminish then rapidly recover after Mpc2 deletion. (A) CD45.2 peripheral blood chimerism of mature cell populations was assessed every 2–3 wk in Mpc2 chimeras. Values are normalized to pre-tamoxifen chimerism of each cell type. Data are pooled from three independent experiments. Mean values ± SEM are shown. ****, P < 0.0001 by paired two-way ANOVA with post-hoc Tukey’s multiple comparisons test. (B and C) CD45.2 peripheral blood chimerism of mature cell populations was assessed every 2 wk in Cpt2 (B) or Gls (C) chimeras. Values are normalized to pre-tamoxifen chimerism of each cell type. Mean values ± SEM are shown. Data are pooled from two independent experiments. P values >0.05 by two-way ANOVA with post-hoc Tukey’s multiple comparisons test are not depicted.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal